Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors

Lundgren, Anna ; Leach, Susannah ; Kaim, Joanna ; Dutta, Nikita ; Li, Ying ; Nilsson, Frida ; Jawad, Ahmed ; Bemark, Mats LU orcid ; Gisslén, Magnus and Hallqvist, Andreas , et al. (2025) In Lung Cancer 209. p.1-6
Abstract

INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) faced an elevated risk for severe COVID-19 outcomes and were prioritized for early vaccination. However, immune responses to SARS-CoV-2 vaccines remain poorly characterized in this group, especially in patients receiving immune checkpoint inhibitor PD-1/PDL-1 (ICI) therapy.

MATERIALS AND METHODS: In this prospective observational study, we evaluated humoral and cellular immune responses to COVID-19 vaccination in 20 NSCLC patients receiving ICI therapy and compared to responses in 38 controls. Patients received two doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (AstraZeneca) vaccines followed by a third dose of BNT162b2 while controls received three doses of... (More)

INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) faced an elevated risk for severe COVID-19 outcomes and were prioritized for early vaccination. However, immune responses to SARS-CoV-2 vaccines remain poorly characterized in this group, especially in patients receiving immune checkpoint inhibitor PD-1/PDL-1 (ICI) therapy.

MATERIALS AND METHODS: In this prospective observational study, we evaluated humoral and cellular immune responses to COVID-19 vaccination in 20 NSCLC patients receiving ICI therapy and compared to responses in 38 controls. Patients received two doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (AstraZeneca) vaccines followed by a third dose of BNT162b2 while controls received three doses of BNT162b2. Serum IgG to the receptor-binding domain (RBD) of the spike protein and T-cell cytokine responses (IFN-γ, IL-2 and TNF) induced by spike peptide stimulation of whole blood were assessed at multiple time points.

RESULTS AND DISCUSSION: After two doses, patients exhibited lower and more variable IgG responses than controls, but a third dose raised antibody levels to match those observed in controls. The largest fold-increase in antibody concentrations after the third dose occurred in patients receiving BNT162b2 after two doses of ChAdOx1-S. T-cell responses were significantly lower in patients after two doses but improved following the third dose. Antibody and IFN-γ responses were significantly correlated both after the second and third doses in patients, suggesting coordinated humoral and cellular immunity. No associations were found between immune responses and patient age. These findings highlight the immunogenicity of COVID-19 vaccines in NSCLC patients on ICI therapy and support that booster vaccinations are needed to enhance immunity in this vulnerable group.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Lung Cancer
volume
209
article number
108770
pages
1 - 6
publisher
Elsevier
external identifiers
  • pmid:41077001
  • scopus:105018350817
ISSN
1872-8332
DOI
10.1016/j.lungcan.2025.108770
language
English
LU publication?
yes
additional info
Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
id
270fa178-8819-4919-bd19-c8af16ea8c3e
date added to LUP
2025-10-15 18:33:43
date last changed
2025-10-17 04:45:30
@article{270fa178-8819-4919-bd19-c8af16ea8c3e,
  abstract     = {{<p>INTRODUCTION: Patients with non-small cell lung cancer (NSCLC) faced an elevated risk for severe COVID-19 outcomes and were prioritized for early vaccination. However, immune responses to SARS-CoV-2 vaccines remain poorly characterized in this group, especially in patients receiving immune checkpoint inhibitor PD-1/PDL-1 (ICI) therapy.</p><p>MATERIALS AND METHODS: In this prospective observational study, we evaluated humoral and cellular immune responses to COVID-19 vaccination in 20 NSCLC patients receiving ICI therapy and compared to responses in 38 controls. Patients received two doses of either BNT162b2 (Pfizer-BioNTech) or ChAdOx1-S (AstraZeneca) vaccines followed by a third dose of BNT162b2 while controls received three doses of BNT162b2. Serum IgG to the receptor-binding domain (RBD) of the spike protein and T-cell cytokine responses (IFN-γ, IL-2 and TNF) induced by spike peptide stimulation of whole blood were assessed at multiple time points.</p><p>RESULTS AND DISCUSSION: After two doses, patients exhibited lower and more variable IgG responses than controls, but a third dose raised antibody levels to match those observed in controls. The largest fold-increase in antibody concentrations after the third dose occurred in patients receiving BNT162b2 after two doses of ChAdOx1-S. T-cell responses were significantly lower in patients after two doses but improved following the third dose. Antibody and IFN-γ responses were significantly correlated both after the second and third doses in patients, suggesting coordinated humoral and cellular immunity. No associations were found between immune responses and patient age. These findings highlight the immunogenicity of COVID-19 vaccines in NSCLC patients on ICI therapy and support that booster vaccinations are needed to enhance immunity in this vulnerable group.</p>}},
  author       = {{Lundgren, Anna and Leach, Susannah and Kaim, Joanna and Dutta, Nikita and Li, Ying and Nilsson, Frida and Jawad, Ahmed and Bemark, Mats and Gisslén, Magnus and Hallqvist, Andreas and Raghavan, Sukanya}},
  issn         = {{1872-8332}},
  language     = {{eng}},
  pages        = {{1--6}},
  publisher    = {{Elsevier}},
  series       = {{Lung Cancer}},
  title        = {{Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors}},
  url          = {{http://dx.doi.org/10.1016/j.lungcan.2025.108770}},
  doi          = {{10.1016/j.lungcan.2025.108770}},
  volume       = {{209}},
  year         = {{2025}},
}